CARDIOME PHARMA CORP CORV Balance Sheet

Cardiome pharma corp (CORV)

Balance Sheet / TTM

Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10
Current assets:
Cash and cash equivalents
22,081	26,758	17,661	12,708	10,984	41,003	48,644	76,888
Restricted cash (note 6)
2,100	2,547	2,196	2,320	2,323	264	-	-
Accounts receivable, net of allowance for doubtful accounts of $125 (2016 - $97)
6,383	6,154	6,814	9,504	6,674	978	1,248	732
Inventories (note 7)
6,427	4,618	4,401	5,335	6,597	0	-	-
Prepaid expenses and other assets
961	1,302	1,408	1,703	1,749	771	628	1,000
Assets, Current
37,952	41,379	32,949	32,009	28,327	43,016	50,520	78,620
Property and equipment (note 8)
416	548	740	811	618	271	1,967	2,069
Intangible assets (note 9)
27,806	24,352	14,221	16,156	18,069	1,506	1,548	1,635
Goodwill
318	318	318	318	318	0	-	-
Deferred income tax assets (note 18)
320	460	469	439	0	-	-	-
Other assets
-	-	-	821	0	-	-	-
Assets
66,812	67,057	48,228	50,115	47,332	44,793	54,035	82,324
Current liabilities:
Accounts payable and accrued liabilities (note 10)
7,701	8,021	10,488	13,057	14,003	4,434	3,188	5,705
Current portion of long-term debt, net of unamortized debt issuance costs (note 10)
-	-	3,912	1,714	0	32,500	0	-
Current portion of deferred consideration (note 12)
0	2,815	2,619	3,044	3,688	0	-	-
Current portion of deferred revenue
207	182	188	0	-	-	-	-
Current portion of deferred leasehold inducement (note 9)
-	-	-	-	-	-	116	216
Liabilities, Current
7,908	11,018	17,207	17,815	17,691	36,934	3,304	5,921
Long-term debt, net of unamortized debt issuance costs and discount (note 11)
40,000	19,391	5,686	10,286	0	-	-	-
Deferred consideration (note 11)
-	-	2,478	4,544	6,997	0	-	-
Deferred revenue
2,502	2,381	2,647	0	-	-	-	-
Other long-term liabilities
212	243	274	331	-	-	-	-
Deferred leasehold inducement (note 9)
-	-	-	-	-	-	445	486
Long-term debt (note 11)
-	-	-	-	-	-	25,000	25,000
Liabilities
50,622	33,033	28,292	32,976	24,688	36,934	28,749	31,407
Stockholders equity:
Common stock Authorized - unlimited number without par value Issued and outstanding - 34,637,312 (2016 - 31,884,420) (note 13(b))
353,483	344,928	312,019	284,760	272,083	262,439	262,097	261,554
Additional paid-in capital (note 14)
38,443	35,812	34,678	34,229	33,349	32,754	32,208	30,462
Deficit
-392,865	-363,054	-343,435	-318,973	-300,746	-305,519	-287,204	-259,284
Accumulated other comprehensive income (note 2(c))
17,129	16,338	16,674	17,123	17,958	18,185	18,185	18,185
Stockholders' Equity
16,190	34,024	19,936	17,139	22,644	7,859	25,286	50,917
Liabilities and Equity
66,812	67,057	48,228	50,115	47,332	44,793	54,035	82,324
Commitments and contingencies (notes 17 and 20)
0	0	-	-	-	-	-	-
Subsequent events (notes 11 and 22)
0	0	-	-	-	-	-	-